Evidence map›Paper›PMID 39183242›Full record

ArticleLa Radiologia medica2024

Clinical value of sequential circulating tumor DNA analysis using next-generation sequencing and epigenetic modifications for guiding thermal ablation for colorectal cancer metastases: a prospective study.

Tom Boeken, Olivier Pellerin, Camille Bourreau, Juliette Palle, Claire Gallois, Aziz Zaanan, Julien Taieb, Widad Lahlou, Alessandro Di Gaeta, Marc Al Ahmar and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tom BoekenDepartment of Vascular and Oncological Interventional Radiology, AP-HP, INSERM PARCC U 970, Hôpital Européen Georges Pompidou, HEKA INRIA, Université de Paris Cité, Paris, France. tom.boeken@aphp.fr.ORCID http://orcid.org/0000-0003-2990-5180
Olivier PellerinDepartment of Vascular and Oncological Interventional Radiology, AP-HP, INSERM PARCC U 970, Hôpital Européen Georges Pompidou, HEKA INRIA, Université de Paris Cité, Paris, France.
Camille BourreauINSERM 1138 Centre de Recherche des Cordeliers, Paris, France.
Juliette PalleDepartment of Gastroenterology and Digestive Oncology, AP-HP, Hôpital Européen Georges Pompidou, SIRIC CARPEM, Université Paris Cité, Paris, France.
Claire GalloisDepartment of Gastroenterology and Digestive Oncology, AP-HP, Hôpital Européen Georges Pompidou, SIRIC CARPEM, Université Paris Cité, Paris, France.
Aziz ZaananDepartment of Gastroenterology and Digestive Oncology, AP-HP, Hôpital Européen Georges Pompidou, SIRIC CARPEM, Université Paris Cité, Paris, France.
Julien TaiebDepartment of Gastroenterology and Digestive Oncology, AP-HP, Hôpital Européen Georges Pompidou, SIRIC CARPEM, Université Paris Cité, Paris, France.
Widad LahlouDepartment of Gastroenterology and Digestive Oncology, AP-HP, Hôpital Européen Georges Pompidou, SIRIC CARPEM, Université Paris Cité, Paris, France.
Alessandro Di GaetaDepartment of Vascular and Oncological Interventional Radiology, AP-HP, INSERM PARCC U 970, Hôpital Européen Georges Pompidou, HEKA INRIA, Université de Paris Cité, Paris, France.
Marc Al AhmarDepartment of Vascular and Oncological Interventional Radiology, AP-HP, INSERM PARCC U 970, Hôpital Européen Georges Pompidou, HEKA INRIA, Université de Paris Cité, Paris, France.
Xavier GuerraDepartment of Vascular and Oncological Interventional Radiology, AP-HP, INSERM PARCC U 970, Hôpital Européen Georges Pompidou, HEKA INRIA, Université de Paris Cité, Paris, France.
Carole DeanUniversité de Paris Cité, Paris, France.
Pierre Laurent PuigDepartment of Biochemistry, Pharmacogenetics and Molecular Oncology (ONSTeP), AP-HP, Hôpital Européen Georges Pompidou, Paris Cancer Institute CARPEM, Université de Paris Cité, Paris, France.
Marc SapovalDepartment of Vascular and Oncological Interventional Radiology, AP-HP, INSERM PARCC U 970, Hôpital Européen Georges Pompidou, HEKA INRIA, Université de Paris Cité, Paris, France.
Helena PereiraCentre d'investigation Clinique 1418 Épidémiologie Clinique, AP-HP, INSERM, Hôpital Européen Georges Pompidou, Clinical Research Unit, Paris, France.
Hélène BlonsDepartment of Biochemistry, Pharmacogenetics and Molecular Oncology (ONSTeP), AP-HP, Hôpital Européen Georges Pompidou, Paris Cancer Institute CARPEM, Université de Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile thermal ablation is now a standard treatment option for oligometastatic colorectal cancer patients, selecting those who will benefit most from locoregional therapies remains challenging. This proof-of-concept study is the first to assess the feasibility of routine testing of ctDNA before and after thermal ablation with curative intent, analyzed by next-generation sequencing (NGS) and methylation specific digital droplet PCR (ddPCR). Our prospective study primary objective was to assess the prognostic value of ctDNA before thermal ablation.

methodsThis single-center prospective study from November 2021 to June 2022 included colorectal cancer patients referred for curative-intent thermal ablation. Cell-free DNA was tested at different time points by next-generation sequencing and detection of WIF1 and NPY genes hypermethylation using ddPCR. The ctDNA was considered positive if either a tumor mutation or hypermethylation was detected; recurrence-free survival was used as the primary endpoint.

resultsThe study enrolled 15 patients, and a total of 60 samples were analyzed. The median follow-up after ablation was 316 days, and median recurrence-free survival was 250 days. CtDNA was positive for 33% of the samples collected during the first 24 h. The hazard ratio for progression according to the presence of baseline circulating tumor DNA was estimated at 0.14 (CI 95%: 0.03-0.65, p = 0.019). The dynamics are provided, and patients with no recurrence were all negative at H24 for ctDNA. DISCUSSION: This study shows the feasibility of routine testing of ctDNA before and after thermal ablation with curative intent. We report that circulating tumor DNA is detectable in patients with low tumor burden using 2 techniques. This study emphasizes the potential of ctDNA for discerning patients who are likely to benefit from thermal ablation from those who may not, which could shape future referrals. The dynamics of ctDNA before and after ablation shed light on the need for further research and larger studies.

Indexed as

Circulating Tumor DNAColorectal NeoplasmsHigh-Throughput Nucleotide SequencingAgedAged, 80 and overBiomarkers, TumorDNA MethylationEpigenesis, GeneticFeasibility StudiesFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProspective StudiesBiomarkers, TumorCirculating Tumor DNACirculating tumor DNA (ctDNA)Colorectal cancerNext-generation sequencing (NGS)Prognostic valueThermal ablation

Identifiers

PMID39183242

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.